While specialty drugs account for only 1 to 2 percent of prescriptions filled in the U.S., those prescriptions account for almost half of the total drug spend, according to a recent article published on Managed Healthcare Executive.
The impact of specialty drugs is “astronomical,” Enterprise Specialty Clinical Solutions Director Susan Trieu says.
“When you go back a few years and think about the advent of hepatitis C drugs and what happened when they hit the market, I don’t think we were prepared for agents that could ramp up specialty spend so quickly,” she said. “Before that, specialty spend was fairly predictable. Now there are more and more drugs increasing specialty spend – and it’s really rocked the healthcare industry as we try to control for that and underwrite it.”
To read the full article on MHE, click here.